Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | CASP1 | P29466 | 1/20 | 0.51 |
| ▸ | CASP7 | P55210 | 1/20 | 0.51 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.47 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30791497 | 0.89 | ALDH1A1 (0.55) | CYP3A4ALDH1A1MEN1KMT2ACASP1 | |
| SCHEMBL13889564 | 0.89 | ALDH1A1 (0.55) | CYP3A4ALDH1A1MEN1KMT2ACASP1 | |
| SCHEMBL933272 | 0.88 | CYP3A4 (0.54) | CYP3A4ALDH1A1MEN1KMT2ACASP1 | |
| SCHEMBL5267380 | 0.87 | ALDH1A1 (0.68) | CYP3A4ALDH1A1MEN1KMT2ACASP1 | |
| SCHEMBL6632328 | 0.85 | ALDH1A1 (0.51) | CYP3A4ALDH1A1MEN1KMT2ACASP1 | |
| SCHEMBL7104453 | 0.84 | ALDH1A1 (0.50) | CYP3A4ALDH1A1MEN1KMT2ACASP1 | |
| SCHEMBL29540809 | 0.84 | ALDH1A1 (0.50) | CYP3A4ALDH1A1MEN1KMT2ACASP1 | |
| SCHEMBL1709100 | 0.81 | NCEH1 (0.54) | CYP3A4ALDH1A1MEN1KMT2ACASP1 | |
| SCHEMBL3267335 | 0.81 | ALDH1A1 (0.50) | CYP3A4ALDH1A1MEN1KMT2ACASP1 | |
| SCHEMBL27383069 | 0.81 | CYP3A4 (0.51) | CYP3A4ALDH1A1MEN1KMT2ACASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1051205-C | Composition for treatment of bacterial wilt | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2000-04-12 | — | — | CN | claimed |
| CN-1090131-A | Be used to prevent and treat the composition of bacterialo wilt disease | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1994-08-03 | — | — | CN | claimed |
| EP-2438078-B1 | NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES | UNIV KANSAS (US) | 2017-10-25 | — | — | EP | disclosed |
| US-9120774-B2 | Novobiocin analogues having modified sugar moieties | UNIVERSITY OF KANSAS (US) | 2015-09-01 | — | — | US | disclosed |
| US-20120252745-A1 | NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-10-04 | — | — | US | disclosed |
| US-8212012-B2 | Novobiocin analogues having modified sugar moieties | UNIVERSITY OF KANSAS (US) | 2012-07-03 | — | — | US | disclosed |
| US-8212011-B2 | Novobiocin analogues | UNIVERSITY OF KANSAS (US) | 2012-07-03 | — | — | US | disclosed |
| EP-2438078-A1 | NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES | UNIVERSITY OF KANSAS (US) | 2012-04-11 | — | — | EP | disclosed |
| US-20110112100-A1 | Hepatitis C Virus Inhibitors | PFIZER INC. | 2011-05-12 | — | — | US | disclosed |
| WO-2011004276-A1 | HEPATITIS C VIRUS INHIBITORS | PFIZER LIMITED (GB) | 2011-01-13 | — | — | WO | disclosed |
| WO-2010096650-A1 | NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES | UNIVERSITY OF KANSAS (US) | 2010-08-26 | — | — | WO | disclosed |
| US-20090187014-A1 | Novobiocin Analogues | UNIVERSITY OF KANSAS | 2009-07-23 | — | — | US | disclosed |
| US-20090163709-A1 | Novobiocin Analogues Having Modified Sugar Moieties | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-06-25 | — | — | US | disclosed |
| EP-1448530-B1 | HETEROARYL CARBOXYLIC ACID AMIDES | BAYER HEALTHCARE AG (DE) | 2007-10-03 | — | — | EP | disclosed |
| EP-1448530-A1 | HETEROARYL CARBOXYLIC ACID AMIDES | Bayer HealthCare AG (DE) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003043991-A1 | HETEROARYL CARBOXYLIC ACID AMIDES | BAYER HEALTHCARE AG (DE) | 2003-05-30 | — | — | WO | disclosed |
| CN-1051205-C | Composition for treatment of bacterial wilt | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2000-04-12 | — | — | CN | disclosed |
| CN-1090131-A | Be used to prevent and treat the composition of bacterialo wilt disease | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1994-08-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163709-A1 | Novobiocin Analogues Having Modified Sugar Moieties | HSP90AB1, HSP90B1, HSP90AB2P | CYP3A4 4380/4885ALDH1A1 3407/4885MEN1 3938/4885 |
| US-20110112100-A1 | Hepatitis C Virus Inhibitors | HAVCR2, SLC10A1, HCCS | CYP3A4 237/4885ALDH1A1 557/4885MEN1 4544/4885 |
| US-20120252745-A1 | NOVOBIOCIN ANALOGUES HAVING MODIFIED SUGAR MOIETIES | HSP90AB1, HSP90AB2P, HSP90B1 | CYP3A4 3151/4885ALDH1A1 3066/4885MEN1 4739/4885 |
| US-20090187014-A1 | Novobiocin Analogues | SSB, SSBP1, BTD | CYP3A4 4317/4885ALDH1A1 4519/4885MEN1 2090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.